Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Caredx Inc's Business Segments
Caredx Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 118
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 118 | 100% |
Revenue Share by Region - Q1 FY2026
- Non-US3.4%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 4 | 3.4% |
Revenue by Product & Service Category - Q1 FY2026
- Service77.7%
- Patient and digital solutions13.6%
- Product8.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 91 | 77.7% |
| Patient and digital solutions | $ 16 | 13.6% |
| Product | $ 10 | 8.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Caredx Inc
CardeDX Inc. is a commercial-stage precision medicine company that specializes in developing clinically actionable diagnostics to advance the field of transplant medicine. The company is based in Brisbane, California, and was founded in 2011. Its products and services are aimed at improving patient outcomes by providing accurate and reliable information about their transplant status.
Caredx's primary focus is on providing organ transplant patients with the latest diagnostic tools to ensure the best possible patient outcomes. The company's products and services are designed to help clinicians predict the likelihood of transplant rejection, monitor transplant patients for potential complications, and provide personalized treatment plans to prevent organ rejection.
Caredx's flagship product, the AlloSure™ test, is a blood test that measures the fraction of donor-derived cell-free DNA circulating in a transplant recipient's bloodstream. The test provides clinicians with valuable information about the health of transplanted organs and helps to identify whether a patient is rejecting the transplant. The AlloSure test is the first and only commercially available test of its kind, and it is currently available in the United States and select international markets.
In addition to the AlloSure test, Caredx also offers a range of other diagnostic solutions for transplant patients, including the AlloMap™ test, which measures the expression of genes associated with organ rejection, and the AlloSeq™ HLA genotyping test, which helps to identify the compatibility between a donor and recipient.
Caredx's services are primarily used by transplant centers, hospitals, and transplant specialists. The company has established partnerships with many leading academic medical centers and transplant organizations in the United States and internationally.
The company has a strong focus on research and development and has invested heavily in building a cutting-edge laboratory facility that allows for the development and testing of novel transplant diagnostics. In addition to developing new products and services, Caredx also works closely with transplant centers and transplant professionals to educate them about the latest advances in transplant diagnostic technology.
Caredx has received numerous awards and recognitions for its innovative products and services, including the 2016 Frost & Sullivan Technology Innovation Award and the 2018 Red Herring Top 100 North America Award.
Overall, Caredx is a leading player in the fast-growing field of precision medicine and is at the forefront of driving innovation and advancement in transplant diagnostics. With a strong commitment to research and development, the company is well-positioned to continue to grow and expand its product offerings and contribute to improving patient outcomes in the field of transplant medicine.
Caredx's primary focus is on providing organ transplant patients with the latest diagnostic tools to ensure the best possible patient outcomes. The company's products and services are designed to help clinicians predict the likelihood of transplant rejection, monitor transplant patients for potential complications, and provide personalized treatment plans to prevent organ rejection.
Caredx's flagship product, the AlloSure™ test, is a blood test that measures the fraction of donor-derived cell-free DNA circulating in a transplant recipient's bloodstream. The test provides clinicians with valuable information about the health of transplanted organs and helps to identify whether a patient is rejecting the transplant. The AlloSure test is the first and only commercially available test of its kind, and it is currently available in the United States and select international markets.
In addition to the AlloSure test, Caredx also offers a range of other diagnostic solutions for transplant patients, including the AlloMap™ test, which measures the expression of genes associated with organ rejection, and the AlloSeq™ HLA genotyping test, which helps to identify the compatibility between a donor and recipient.
Caredx's services are primarily used by transplant centers, hospitals, and transplant specialists. The company has established partnerships with many leading academic medical centers and transplant organizations in the United States and internationally.
The company has a strong focus on research and development and has invested heavily in building a cutting-edge laboratory facility that allows for the development and testing of novel transplant diagnostics. In addition to developing new products and services, Caredx also works closely with transplant centers and transplant professionals to educate them about the latest advances in transplant diagnostic technology.
Caredx has received numerous awards and recognitions for its innovative products and services, including the 2016 Frost & Sullivan Technology Innovation Award and the 2018 Red Herring Top 100 North America Award.
Overall, Caredx is a leading player in the fast-growing field of precision medicine and is at the forefront of driving innovation and advancement in transplant diagnostics. With a strong commitment to research and development, the company is well-positioned to continue to grow and expand its product offerings and contribute to improving patient outcomes in the field of transplant medicine.
Caredx Inc. - Comprehensive Overview of Segments, Products, and Services
Segments:
Caredx Inc. operates primarily in the realm of precision medicine, specializing in molecular diagnostic solutions tailored for transplant patients. Their offerings are structured into three core segments:
1. Transplant Diagnostics:
Caredx’s premier product in this segment is AlloSure, a non-invasive genomic test that quantifies donor-derived cell-free DNA in the bloodstream of transplant patients. AlloSure is instrumental in the early detection of transplant rejection, enabling healthcare providers to proactively monitor patients who have undergone kidney, heart, lung, or liver transplants. This genomic testing facilitates a more precise understanding of the patients response to the transplanted organ, significantly enhancing patient management and outcomes.
2. Clinical Laboratory Services:
Caredx boasts a fully accredited clinical laboratory that delivers a comprehensive array of diagnostic testing services specifically for transplant candidates and recipients. These services include:
- HLA Typing: Utilized to match patients with suitable organ donors by identifying Human Leukocyte Antigen (HLA) compatibility.
- Antibody Detection: Identifies the presence of anti-HLA antibodies that may predispose patients to transplant rejection.
- Gene Expression Profiling: This approach aids in monitoring the immune response in transplant patients, providing crucial insights into their transplant status and potential rejection.
3. Consumer Genomics:
Caredx has expanded its portfolio into the consumer genomics arena with the Hereditary Cancer Panel. This offering involves a direct-to-consumer genetic testing service that evaluates an individual’s DNA for 33 genes associated with hereditary cancer risks. This segment allows individuals to gain insights into their genetic predispositions, empowering proactive health management.
Products:
Caredx offers a diverse range of diagnostic products designed to enhance the management of transplant patients effectively. Key products include:
1. AlloSure: A groundbreaking non-invasive blood test that signifies the presence of donor-derived cell-free DNA, allowing for real-time assessment of transplant rejection.
2. AlloMap: This gene expression profiling test is tailored specifically for heart transplant recipients, enabling healthcare providers to continually monitor the patients immune response and identify potential rejection.
3. AlloSeq: A next-generation sequencing test that offers comprehensive HLA typing, facilitating the identification of the most compatible donor for transplant candidates.
4. Olerup QTYPE: This PCR-based HLA typing test helps determine which donor is the best match for a transplant recipient, enhancing the chances of transplant success.
Services:
Caredx’s clinical laboratory also delivers critical diagnostic testing services, which include:
1. HLA Typing: This service identifies the patients specific HLA alleles, supporting optimal donor-patient matching to minimize rejection risks and improve transplant outcomes.
2. Antibody Detection: Tests are performed to detect anti-HLA antibodies in the patient’s blood, which is crucial for assessing transplant compatibility.
3. Gene Expression Profiling: Caredx provides several gene expression profiling tests, including AlloMap for heart transplant patients and AlloMap Kidney, which assists in monitoring kidney transplant recipients.
4. Bioinformatics: The incorporation of bioinformatics techniques allows Caredx to analyze extensive genomic datasets effectively. This analytical support conveys personalized treatment recommendations, enhancing the overall management and care of transplant patients.
In summary, Caredx Inc. delivers a robust suite of products and services that significantly improve the landscape of transplant medicine. Their commitment to precision diagnostics, from pre-transplant evaluations to ongoing post-transplant monitoring, positions them at the forefront of enhancing patient outcomes in the field of transplantation.
Segments:
Caredx Inc. operates primarily in the realm of precision medicine, specializing in molecular diagnostic solutions tailored for transplant patients. Their offerings are structured into three core segments:
1. Transplant Diagnostics:
Caredx’s premier product in this segment is AlloSure, a non-invasive genomic test that quantifies donor-derived cell-free DNA in the bloodstream of transplant patients. AlloSure is instrumental in the early detection of transplant rejection, enabling healthcare providers to proactively monitor patients who have undergone kidney, heart, lung, or liver transplants. This genomic testing facilitates a more precise understanding of the patients response to the transplanted organ, significantly enhancing patient management and outcomes.
2. Clinical Laboratory Services:
Caredx boasts a fully accredited clinical laboratory that delivers a comprehensive array of diagnostic testing services specifically for transplant candidates and recipients. These services include:
- HLA Typing: Utilized to match patients with suitable organ donors by identifying Human Leukocyte Antigen (HLA) compatibility.
- Antibody Detection: Identifies the presence of anti-HLA antibodies that may predispose patients to transplant rejection.
- Gene Expression Profiling: This approach aids in monitoring the immune response in transplant patients, providing crucial insights into their transplant status and potential rejection.
3. Consumer Genomics:
Caredx has expanded its portfolio into the consumer genomics arena with the Hereditary Cancer Panel. This offering involves a direct-to-consumer genetic testing service that evaluates an individual’s DNA for 33 genes associated with hereditary cancer risks. This segment allows individuals to gain insights into their genetic predispositions, empowering proactive health management.
Products:
Caredx offers a diverse range of diagnostic products designed to enhance the management of transplant patients effectively. Key products include:
1. AlloSure: A groundbreaking non-invasive blood test that signifies the presence of donor-derived cell-free DNA, allowing for real-time assessment of transplant rejection.
2. AlloMap: This gene expression profiling test is tailored specifically for heart transplant recipients, enabling healthcare providers to continually monitor the patients immune response and identify potential rejection.
3. AlloSeq: A next-generation sequencing test that offers comprehensive HLA typing, facilitating the identification of the most compatible donor for transplant candidates.
4. Olerup QTYPE: This PCR-based HLA typing test helps determine which donor is the best match for a transplant recipient, enhancing the chances of transplant success.
Services:
Caredx’s clinical laboratory also delivers critical diagnostic testing services, which include:
1. HLA Typing: This service identifies the patients specific HLA alleles, supporting optimal donor-patient matching to minimize rejection risks and improve transplant outcomes.
2. Antibody Detection: Tests are performed to detect anti-HLA antibodies in the patient’s blood, which is crucial for assessing transplant compatibility.
3. Gene Expression Profiling: Caredx provides several gene expression profiling tests, including AlloMap for heart transplant patients and AlloMap Kidney, which assists in monitoring kidney transplant recipients.
4. Bioinformatics: The incorporation of bioinformatics techniques allows Caredx to analyze extensive genomic datasets effectively. This analytical support conveys personalized treatment recommendations, enhancing the overall management and care of transplant patients.
In summary, Caredx Inc. delivers a robust suite of products and services that significantly improve the landscape of transplant medicine. Their commitment to precision diagnostics, from pre-transplant evaluations to ongoing post-transplant monitoring, positions them at the forefront of enhancing patient outcomes in the field of transplantation.